HighVista Strategies LLC Increases Position in Vera Therapeutics, Inc. $VERA

HighVista Strategies LLC increased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 125.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,189 shares of the company’s stock after buying an additional 50,716 shares during the quarter. HighVista Strategies LLC owned 0.14% of Vera Therapeutics worth $2,650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vestal Point Capital LP lifted its position in Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Vera Therapeutics by 47.8% in the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after purchasing an additional 550,000 shares during the period. Braidwell LP purchased a new position in shares of Vera Therapeutics in the third quarter worth about $13,738,000. Capricorn Fund Managers Ltd purchased a new position in shares of Vera Therapeutics in the third quarter worth about $13,097,000. Finally, American Century Companies Inc. lifted its holdings in shares of Vera Therapeutics by 89.3% during the second quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock worth $16,832,000 after purchasing an additional 336,978 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $39.96 on Monday. The business has a 50-day moving average of $43.81 and a 200 day moving average of $36.96. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $56.05. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of -8.58 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the previous year, the business earned ($0.72) earnings per share. As a group, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, SVP Joseph R. Young sold 3,117 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the transaction, the senior vice president owned 64,722 shares in the company, valued at $2,717,029.56. This represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William D. Turner sold 2,187 shares of Vera Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the sale, the insider owned 45,313 shares in the company, valued at $1,902,239.74. This trade represents a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 33,490 shares of company stock valued at $1,405,910 over the last three months. 16.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on VERA shares. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Pivotal Research set a $73.00 price target on Vera Therapeutics in a report on Friday, December 5th. The Goldman Sachs Group increased their price target on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. HC Wainwright boosted their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.45.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.